Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609045 | 1.00 | CTSK (0.55) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL1194009 | 1.00 | CTSK (0.55) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL18989601 | 0.88 | CTSK (0.51) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL18989589 | 0.88 | CTSK (0.51) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL7877056 | 0.85 | MIF (0.47) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL5500503 | 0.85 | CTSK (0.41) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL18989452 | 0.84 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL18989598 | 0.84 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL18989457 | 0.84 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL391359 | 0.84 | TRPA1 (0.47) | CTSKCTSSMAPTCTSLPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7834037-B2 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | LTC4S, ALOX5, LTA4H | CTSK 3669/4885CTSS 3609/4885MAPT 4698/4885 |
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | ALOX5, ALOX15B, ALOX15 | CTSK 1958/4885CTSS 1585/4885MAPT 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.